Pharmacy Times articleshttps://www.pharmacytimes.com/newsPharmacy Times articles© 2026 MJH Life Sciences™ and Pharmacy Times. All rights reserved.Sat, 29 Aug 2026 14:50:06 +00005en-us14447https://www.pharmacytimes.com/newshttps://www.pharmacytimes.com/logo.webphttps://www.pharmacytimes.com/view/managing-tarlatamab-toxicity-a-practical-guide-for-oncology-pharmacistshttps://www.pharmacytimes.com/view/managing-tarlatamab-toxicity-a-practical-guide-for-oncology-pharmacists<![CDATA[Tarlatamab targets DLL3 in lung cancer; learn step-up dosing, CRS/ICANS monitoring, and pharmacy tips to keep patients safely on therapy.]]>Fri, 28 Aug 2026 20:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/esc-2026-hot-line-recap-3-trials-every-pharmacist-needshttps://www.pharmacytimes.com/view/esc-2026-hot-line-recap-3-trials-every-pharmacist-needs<![CDATA[Craig Beavers, PharmD, breaks down CARDIO-TTRansform, SINGLE-AF, and POET II—and what each means for anticoagulation, stewardship, and monitoring]]>Fri, 28 Aug 2026 16:01:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/tirzepatide-cuts-health-care-costs-in-older-adults-with-obesityhttps://www.pharmacytimes.com/view/tirzepatide-cuts-health-care-costs-in-older-adults-with-obesity<![CDATA[Real-world data show sustained tirzepatide use offset its price by 12 months in adults over 55, with fewer hospital and ED visits.]]>Fri, 28 Aug 2026 16:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-approves-bixlenvo-once-daily-single-tablet-regimen-for-virologically-suppressed-adults-with-hivhttps://www.pharmacytimes.com/view/fda-approves-bixlenvo-once-daily-single-tablet-regimen-for-virologically-suppressed-adults-with-hiv<![CDATA[Bictegravir/lenacapavir (Bixlenvo) offers the first single-tablet option for many patients with HIV currently receiving complex antiretroviral regimens. ]]>Fri, 28 Aug 2026 15:08:07 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-approves-tirzepatide-to-cut-cv-risk-in-type-2-diabeteshttps://www.pharmacytimes.com/view/fda-approves-tirzepatide-to-cut-cv-risk-in-type-2-diabetes<![CDATA[Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.]]>Fri, 28 Aug 2026 13:33:15 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/building-the-pharmacy-of-the-future-trust-loyalty-and-growthhttps://www.pharmacytimes.com/view/building-the-pharmacy-of-the-future-trust-loyalty-and-growth<![CDATA[McPhillips and James make the business case for at-home testing as a win-win for patients and pharmacies, and close with advice for pharmacists hesitant to add self-testing counseling to their workflow.]]>Fri, 28 Aug 2026 12:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/beyond-crs-and-icans-managing-the-delayed-toxicities-of-cilta-celhttps://www.pharmacytimes.com/view/beyond-crs-and-icans-managing-the-delayed-toxicities-of-cilta-cel<![CDATA[Experts gather for a roundtable on the rare, delayed toxicities associated with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.]]>Fri, 28 Aug 2026 10:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-approves-xfg-adapted-covid-19-vaccine-mrna-for-the-2026-2027-seasonhttps://www.pharmacytimes.com/view/fda-approves-xfg-adapted-covid-19-vaccine-mrna-for-the-2026-2027-season<![CDATA[The updated formula targets the JN. 1-lineage XFG variant and begins shipping immediately to pharmacies, hospitals, and clinics nationwide.]]>Thu, 27 Aug 2026 21:02:51 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-approves-first-oral-drug-for-dermatomyositishttps://www.pharmacytimes.com/view/fda-approves-first-oral-drug-for-dermatomyositis<![CDATA[Brepocitinib (Lisraya), a once-daily TYK2-JAK1 inhibitor, is the first oral therapy approved for adults with the rare autoimmune disease.]]>Thu, 27 Aug 2026 20:52:42 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-grants-fast-track-designation-to-varsetatug-masetecan-for-metastatic-colorectal-cancerhttps://www.pharmacytimes.com/view/fda-grants-fast-track-designation-to-varsetatug-masetecan-for-metastatic-colorectal-cancer<![CDATA[Early-phase trial data showed antitumor activity in heavily pretreated metastatic colorectal cancer.]]>Thu, 27 Aug 2026 19:55:54 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/what-heidi-overton-s-fda-nomination-could-mean-for-pharmacyhttps://www.pharmacytimes.com/view/what-heidi-overton-s-fda-nomination-could-mean-for-pharmacy<![CDATA[If confirmed, the FDA nominee's views on abortion pills, vaccines, and drug review could reshape pharmacists' daily work.]]>Thu, 27 Aug 2026 18:24:57 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/ivonescimab-combination-improves-overall-survival-in-first-line-advanced-biliary-tract-cancerhttps://www.pharmacytimes.com/view/ivonescimab-combination-improves-overall-survival-in-first-line-advanced-biliary-tract-cancer<![CDATA[Ivonescimab plus chemotherapy significantly improved overall survival compared with durvalumab plus chemotherapy in patients with previously untreated advanced biliary tract cancer. ]]>Thu, 27 Aug 2026 18:10:09 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/reading-ckm-signals-together-a-pharmacist-s-guidehttps://www.pharmacytimes.com/view/reading-ckm-signals-together-a-pharmacist-s-guide<![CDATA[Andrew Bzowyckyj, PharmD, explains how pharmacists can use albuminuria, ejection fraction, and inflammation to drive earlier CKM risk stratification and patient care.]]>Thu, 27 Aug 2026 18:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/a-new-dual-glucose-ketone-monitor-expert-perspectivehttps://www.pharmacytimes.com/view/a-new-dual-glucose-ketone-monitor-expert-perspective<![CDATA[A diabetologist who lives with type 1 diabetes weighs in on real-time ketone monitoring and what it means for at-risk patients.]]>Thu, 27 Aug 2026 16:00:35 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/oral-vs-intravenous-treatment-logisticshttps://www.pharmacytimes.com/view/oral-vs-intravenous-treatment-logistics<![CDATA[Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, challenges the assumption that oral agents (belumosudil) are inherently more convenient than intravenous therapy (axatilimab) by highlighting that the intravenous schedule creates structured monitoring touchpoints and that mechanism differences—not route alone—should drive sequencing decisions in heavily pretreated populations.]]>Thu, 27 Aug 2026 12:55:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/beyond-the-transplant-center-iv-therapy-in-the-communityhttps://www.pharmacytimes.com/view/beyond-the-transplant-center-iv-therapy-in-the-community<![CDATA[Brooke Adams, PharmD, BCOP, walks through the operational mechanics of transitioning cGVHD patients to community settings: coordination touchpoints, common failure points, and 90-day post-transition checkpoints that confirm a successful handoff.]]>Thu, 27 Aug 2026 12:50:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/incorporating-patient-reported-symptoms-into-treatment-planshttps://www.pharmacytimes.com/view/incorporating-patient-reported-symptoms-into-treatment-plans<![CDATA[Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, addresses the tension between objective NIH scoring and subjective patient experience, and how pharmacists can document patient-reported outcomes to support clinical recommendations, particularly when partial responses demonstrate meaningful functional improvement.]]>Thu, 27 Aug 2026 12:45:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/patient-reported-outcomes-and-quality-of-life-with-axatilimab-in-cgvhdhttps://www.pharmacytimes.com/view/patient-reported-outcomes-and-quality-of-life-with-axatilimab-in-cgvhd<![CDATA[Brooke Adams, PharmD, BCOP, explores how patient narratives on axatilimab inform treatment decisions, moving beyond National Institutes of Health response criteria to functional outcomes—return to work or family activities, reduction in pain or skin discomfort, improved sleep—and how these improvements may exceed what clinical response rates alone predict.]]>Thu, 27 Aug 2026 12:40:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/safety-monitoring-protocols-during-transitions-of-carehttps://www.pharmacytimes.com/view/safety-monitoring-protocols-during-transitions-of-care<![CDATA[Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, describes the pharmacist-to-pharmacist handoff workflow when patients with cGVHD transition from the transplant center to outpatient or home infusion settings, including essential documentation elements, baseline assessments, and red-flag symptoms that require immediate clinical contact.]]>Thu, 27 Aug 2026 12:35:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/adverse-effect-management-and-safety-monitoring-with-axatilimabhttps://www.pharmacytimes.com/view/adverse-effect-management-and-safety-monitoring-with-axatilimab<![CDATA[Brooke Adams, PharmD, BCOP, identifies the clinically meaningful adverse effects every pharmacist must monitor—periorbital edema, hepatic enzyme elevations, fatigue—and specifies intervention thresholds (grading, dose modifications, hold criteria) that should trigger escalation conversations with prescribers.]]>Thu, 27 Aug 2026 12:30:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/learning-from-real-world-experience-with-axatilimabhttps://www.pharmacytimes.com/view/learning-from-real-world-experience-with-axatilimab<![CDATA[Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, discusses how axatilimab performs in actual practice versus what AGAVE-201 predicted, including responses in organ manifestations not well-represented in the trial and how real-world monitoring protocols have evolved based on accumulated clinical experience.]]>Thu, 27 Aug 2026 12:25:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/axatilimab-vs-belumosudil-what-the-data-actually-tell-ushttps://www.pharmacytimes.com/view/axatilimab-vs-belumosudil-what-the-data-actually-tell-us<![CDATA[Brooke Adams, PharmD, BCOP, walks through the axatilimab trial data (AGAVE-201) and belumosudil trial populations, highlighting how differences in study design, patient characteristics, and end points affect pharmacist interpretation and comparability, and what gaps exist in the evidence base for specific organ manifestations.]]>Thu, 27 Aug 2026 12:20:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/understanding-axatilimab-s-mechanism-in-the-context-of-multiple-lines-of-therapyhttps://www.pharmacytimes.com/view/understanding-axatilimab-s-mechanism-in-the-context-of-multiple-lines-of-therapy<![CDATA[Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, translates the CSF1R-targeted mechanism into practical pharmacist workflows: distinct toxicity profiles (periorbital edema, hepatic enzyme elevations), drug interaction review for polypharmacy, and how to communicate the mechanistic rationale to patients and community pharmacy teams.]]>Thu, 27 Aug 2026 12:15:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/mechanisms-of-action-in-cgvhd-therapy-why-the-target-mattershttps://www.pharmacytimes.com/view/mechanisms-of-action-in-cgvhd-therapy-why-the-target-matters<![CDATA[Brook Adams, PharmD, BCOP, explains axatilimab's distinct mechanism targeting the CSF1R pathway on macrophages and monocytes—as opposed to T-cell pathways (ibrutinib) or JAK/STAT signaling (ruxolitinib)—and why this mechanistic differentiation is clinically meaningful when patients have already progressed on other agents.]]>Thu, 27 Aug 2026 12:10:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/where-axatilimab-fits-in-the-formularyhttps://www.pharmacytimes.com/view/where-axatilimab-fits-in-the-formulary<![CDATA[Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, discusses how axatilimab fits into formulary placement and treatment sequencing decisions at her institution, including how the multidisciplinary transplant team aligns on when to initiate therapy and whether clinical scenarios exist where the conversation might occur earlier than strictly third-line.]]>Thu, 27 Aug 2026 12:05:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/from-rationale-to-results-tyrosine-kinase-inhibitors-in-systemic-mastocytosishttps://www.pharmacytimes.com/view/from-rationale-to-results-tyrosine-kinase-inhibitors-in-systemic-mastocytosis<![CDATA[Led by the moderator, the panelists discussed the rationale for targeting the KIT D816V mutation with tyrosine kinase inhibitors and reviewed six-month and three-year PIONEER trial data showing sustained reductions in symptom burden and improved quality of life with avapritinib in indolent systemic mastocytosis, with minimal treatment discontinuation due to adverse events.]]>Thu, 27 Aug 2026 12:05:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/treating-systemic-mastocytosis-from-antihistamines-to-targeted-therapyhttps://www.pharmacytimes.com/view/treating-systemic-mastocytosis-from-antihistamines-to-targeted-therapy<![CDATA[The panelists examined how treatment goals differ between indolent and advanced systemic mastocytosis (SM) — the former focused on symptom control and quality of life, the latter also targeting disease modification to reduce mast cell burden and organ damage — and outlined the pharmacist's role in acute anaphylaxis management, including patient education on epinephrine use and antihistamine dosing.]]>Thu, 27 Aug 2026 12:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/cgvhd-today-and-where-axatilimab-fitshttps://www.pharmacytimes.com/view/cgvhd-today-and-where-axatilimab-fits<![CDATA[Brooke Adams, PharmD, BCOP, describes the clinical reality of third-line cGVHD: patients with relapsed or refractory disease after steroids, calcineurin inhibitors, and at least 1 approved second-line agent. ]]>Thu, 27 Aug 2026 12:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/yeast-based-universal-flu-vaccine-fully-protects-mice-against-3-influenza-strainshttps://www.pharmacytimes.com/view/yeast-based-universal-flu-vaccine-fully-protects-mice-against-3-influenza-strains<![CDATA[Investigators say the nanoparticle candidate's speedy manufacturing process and slow-mutating target could reshape how the field responds to emerging flu strains.]]>Wed, 26 Aug 2026 20:21:18 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/screen-stage-sequence-ckd-care-pharmacists-can-leadhttps://www.pharmacytimes.com/view/screen-stage-sequence-ckd-care-pharmacists-can-lead<![CDATA[Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.]]>Wed, 26 Aug 2026 20:00:00 GMTPharmacy TimesusPharmacy Times Articles